Cargando…

Bayesian multi-source regression and monocyte-associated gene expression predict BCL-2 inhibitor resistance in acute myeloid leukemia

The FDA recently approved eight targeted therapies for acute myeloid leukemia (AML), including the BCL-2 inhibitor venetoclax. Maximizing efficacy of these treatments requires refining patient selection. To this end, we analyzed two recent AML studies profiling the gene expression and ex vivo drug r...

Descripción completa

Detalles Bibliográficos
Autores principales:	White, Brian S., Khan, Suleiman A., Mason, Mike J., Ammad-ud-din, Muhammad, Potdar, Swapnil, Malani, Disha, Kuusanmäki, Heikki, Druker, Brian J., Heckman, Caroline, Kallioniemi, Olli, Kurtz, Stephen E., Porkka, Kimmo, Tognon, Cristina E., Tyner, Jeffrey W., Aittokallio, Tero, Wennerberg, Krister, Guinney, Justin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8302655/ https://www.ncbi.nlm.nih.gov/pubmed/34302041 http://dx.doi.org/10.1038/s41698-021-00209-9

Ejemplares similares

Systematic identification of feature combinations for predicting drug response with Bayesian multi-view multi-task linear regression
por: Ammad-ud-din, Muhammad, et al.
Publicado: (2017)

Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies
por: Yadav, Bhagwan, et al.
Publicado: (2014)

Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors
por: Pietarinen, Paavo O., et al.
Publicado: (2017)

Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia
por: Malani, Disha, et al.
Publicado: (2022)

Impact of normalization methods on high-throughput screening data with high hit rates and drug testing with dose–response data
por: Mpindi, John-Patrick, et al.
Publicado: (2015)

Breeze 2.0: an interactive web-tool for visual analysis and comparison of drug response data
por: Potdar, Swapnil, et al.
Publicado: (2023)

Breeze: an integrated quality control and data analysis application for high-throughput drug screening
por: Potdar, Swapnil, et al.
Publicado: (2020)

Patient-tailored design for selective co-inhibition of leukemic cell subpopulations
por: Ianevski, Aleksandr, et al.
Publicado: (2021)

Global proteomics profiling improves drug sensitivity prediction: results from a multi-omics, pan-cancer modeling approach
por: Ali, Mehreen, et al.
Publicado: (2018)

Novel Screening Method Identifies PI3Kα, mTOR, and IGF1R as Key Kinases Regulating Cardiomyocyte Survival
por: Elmadani, Manar, et al.
Publicado: (2019)

What is synergy? The Saariselkä agreement revisited
por: Tang, Jing, et al.
Publicado: (2015)

TIMMA-R: an R package for predicting synergistic multi-targeted drug combinations in cancer cell lines or patient-derived samples
por: He, Liye, et al.
Publicado: (2015)

Searching for Drug Synergy in Complex Dose–Response Landscapes Using an Interaction Potency Model
por: Yadav, Bhagwan, et al.
Publicado: (2015)

Corrigendum to “Searching for drug synergy in complex dose–response landscapes using an interaction potency model” [Comput. Struct. Biotechnol. J. 13 (2015) 504–513]
por: Yadav, Bhagwan, et al.
Publicado: (2017)

A normalized drug response metric improves accuracy and consistency of anticancer drug sensitivity quantification in cell-based screening
por: Gupta, Abhishekh, et al.
Publicado: (2020)

Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML
por: Malani, D, et al.
Publicado: (2017)

FLT3-ITD allelic ratio and HLF expression predict FLT3 inhibitor efficacy in adult AML
por: Kivioja, Jarno, et al.
Publicado: (2021)

Idelalisib sensitivity and mechanisms of disease progression in relapsed TCF3-PBX1 acute lymphoblastic leukemia
por: Eldfors, S, et al.
Publicado: (2017)

An immunity and pyroptosis gene-pair signature predicts overall survival in acute myeloid leukemia
por: Kong, Weikaixin, et al.
Publicado: (2022)

Identification of structural features in chemicals associated with cancer drug response: a systematic data-driven analysis
por: Khan, Suleiman A., et al.
Publicado: (2014)

Identification of novel regulators of STAT3 activity
por: Parri, Elina, et al.
Publicado: (2020)

Improved detection of differentially represented DNA barcodes for high‐throughput clonal phenomics
por: Akimov, Yevhen, et al.
Publicado: (2020)

From drug response profiling to target addiction scoring in cancer cell models
por: Yadav, Bhagwan, et al.
Publicado: (2015)

Targeting Apoptosis Pathways With BCL2 and MDM2 Inhibitors in Adult B-cell Acute Lymphoblastic Leukemia
por: Hohtari, Helena, et al.
Publicado: (2022)

Drug sensitivity profiling identifies potential therapies for lymphoproliferative disorders with overactive JAK/STAT3 signaling
por: Kuusanmäki, Heikki, et al.
Publicado: (2017)

Multi-parametric single cell evaluation defines distinct drug responses in healthy hematologic cells that are retained in corresponding malignant cell types
por: Majumder, Muntasir M., et al.
Publicado: (2020)

Novel drug candidates for blast phase chronic myeloid leukemia from high-throughput drug sensitivity and resistance testing
por: Pietarinen, P O, et al.
Publicado: (2015)

Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia
por: Kuusanmäki, Heikki, et al.
Publicado: (2020)

Target Inhibition Networks: Predicting Selective Combinations of Druggable Targets to Block Cancer Survival Pathways
por: Tang, Jing, et al.
Publicado: (2013)

Seed-effect modeling improves the consistency of genome-wide loss-of-function screens and identifies synthetic lethal vulnerabilities in cancer cells
por: Jaiswal, Alok, et al.
Publicado: (2017)

Identification of selective cytotoxic and synthetic lethal drug responses in triple negative breast cancer cells
por: Gautam, Prson, et al.
Publicado: (2016)

Ex vivo venetoclax sensitivity testing predicts treatment response in acute myeloid leukemia
por: Kuusanmäki, Heikki, et al.
Publicado: (2022)

Intrinsic resistance to PIM kinase inhibition in AML through p38α-mediated feedback activation of mTOR signaling
por: Brunen, Diede, et al.
Publicado: (2016)

Comprehensive data-driven analysis of the impact of chemoinformatic structure on the genome-wide biological response profiles of cancer cells to 1159 drugs
por: Khan, Suleiman A, et al.
Publicado: (2012)

RUNX1 mutations in blast-phase chronic myeloid leukemia associate with distinct phenotypes, transcriptional profiles, and drug responses
por: Adnan Awad, Shady, et al.
Publicado: (2020)

Identification of precision treatment strategies for relapsed/refractory multiple myeloma by functional drug sensitivity testing
por: Majumder, Muntasir Mamun, et al.
Publicado: (2017)

Computational-experimental approach to drug-target interaction mapping: A case study on kinase inhibitors
por: Cichonska, Anna, et al.
Publicado: (2017)

Discovery and functional characterization of a germline, CSF2RB-activating mutation in leukemia
por: Watanabe-Smith, Kevin, et al.
Publicado: (2016)

Genomic markers of midostaurin drug sensitivity in FLT3 mutated and FLT3 wild-type acute myeloid leukemia patients
por: Rosenberg, Mara W., et al.
Publicado: (2020)

Drug Target Commons 2.0: a community platform for systematic analysis of drug–target interaction profiles
por: Tanoli, ZiaurRehman, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_2be1i91gclo6pm11qvkh799r9e